Openbookopenbook
Equity
GILD
+0.0 · +0.00%
USD · NASDAQ

Gilead Sciences Inc(GILD) Stock Analysis | Healthcare

USD --+0.00%
Reward59Moderate
Risk14Low
75%Data
Thin -11% profit margin · 2.2% dividend yield · Revenue growing 10% YoY
Defensive Anchor
Market Cap:181.18Bn
ⓘ
Reward Rating
59
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
14
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GILD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for GILD, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $157.41.

What is Gilead Sciences Inc?

, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD · Verdict

Solid reward · low risk

GILD stands out on volatility and cash flow, but watch the valuation signal.

Based on 88% data coverage

GILD · Verdict

What’s working & what to watch

Strengths 4

  • Volatility95/100

    Top decile vs peers

  • Cash flow86/100

    32% free-cash-flow margin

  • Profitability84/100

    29% net margin · -21% ROE

  • Balance sheet73/100

    Interest covered 10.6×

Watchouts 1

  • Valuation40/100

    P/E 15.2× · PEG 2.14

Model-based scoring. For information only — not financial advice.

What is Gilead Sciences Inc?

, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 181.18B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

NVOLarge Cap / 201B market cap
Novo Nordisk A/S
Compare
PFELarge Cap / 153B market cap
Pfizer Inc
Compare
AMGNLarge Cap / 238B market cap
Amgen Inc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap181.18B
P/E RatioN/A
Dividend Yield2.24%
Beta0.336
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
412,000 shares
$1.7M
0
6-9months
12309,280 shares
$43.9M
0
9-12months
27,805 shares
$982k
0
2 disclosures without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.